George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
What Debt mountain? - that belongs to Haleon now
It amazes me that after years of being slated for having too generous a dividend GSK is now told the dividend must now be increased. Seriously GSK cannot seem to please anyone. AZ remains the darling despite being totally over valued and dependent on a charismatic leader that won't be there much longer.
1405p to buy? What the hell was that all about?
Investors expecting a raised dividend?
I added to my holding as the drip drip effect of all the positive news of late will surely have an effect in the long term.
Debt mountain and Zantac remain negatives but can be overcome in the medium term.
One for the SIPP
Well it turned out to be interesting. Management did, of course, cover the upgrade with pride but most of the presentation was spend on the progress of recent drug launches and the pipeline. All the analysts questions were about about this some of it, I admit, was above my head but the flavour was positive. They were trying to get a handle on how much to upgrade their forecasts for YE 2024. One that stands out is "Arexvy" (It was approved by the US FDA on May 3rd, 2023, for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in adults aged 60 and older.)
We have clear profit guidance for this year although further strengthening of sterling against US dollar compared with last year would be a negative. Cash generation looks OK and margins are up. The CEO was absolutely clear there is "sustained momentum" and referred to 2026. If the board watch the share price (and they do) they will be gutted to see a fall on the day they make an upgrade for the year 2024. But this is a market and when there are more sellers than buyers we know what happens. I expect the forecasts for the next two years to be raised and its not as though it is a highly rated share today so I have given it a "weak buy" rating. I'm not too concerned about the dividend not rising, it yields enough already!
Almost a chart sell? What about USA Court cases averting.I agree price looks appealing
Dormus
What does it need to do? It needs to up the dividend from 56.5p.
If EPS is increasing then why is the divided not increasing at the same rate?
The dividend pay out ratio is set at between 40% & 60% and un adjusted EPS for 3 months is 113p plus assume another 36p for Q4. The annual dividend should be between 59.6p and 89.4p.
Am I seeing things? All the initial gain on very decent figures just wiped out and replaced by a minus. This was too much for me so I topped up. What has GSK got to do to persuade the market it is the ONLY sizeable pharma in UK to be firing on all cylinders?
I will join the 12.00 GMT Webcast of the results to try to get the flavour behind what, on the face of it, is a meaningful upgrade for the year. If I have any comments I will come back to this thread with them.
No - no increase in dividend. The 56.5p for the year was previously announced.
And quarterly dividend increased again .
Very pleased I bought these earlier this year.
Promise of material growth over 3-5 years and could double from here eventually as the discount with larger peers closes.
All IMHO DYOR
Happy
Nearly all GSK news has been very positive lately and nearly all the items in these results are excellent
Will the market pull a rabbit out of the hat again ie a case of the glass being 1% empty ?
Results look excellent to me surely the share price has to go up off the back of this, but nothing surprises me these days as good results don't seem to count for much
Strong cash generation this Q... will be appreciated by the market.
Surely we will get an up day today after those results. Good momentum
Excellent Q3 results this morning with all estimates uplifted, and not by small amounts.
Should be enough to see the SP whacked at the open. :)
The motto with this company is - "Any news is bad news"
Trojan,
GSK Jenperli approved by FDA in USA
Article in Barrons this morning saying uptake for RSV vaccines is strong. Prescription data reviewed by Jeffries suggests Pfizer have a 35% market share and GSK 65% share. Three weeks ago Bloomberg estimated RSV sales would be $2bn in 2023, giving GSK sales this year of £1074m vs £219m included in consensus sales. An upside of £855m. It will be interesting to see what Luke Miels says about the potential for Arexvy at the Q3 results next week.
Last line of my post should read 'from £25 to perhaps £26'.'
...where I*can understand cos are reluctant to publish RNS even with great news because the market is on such a downward slope that it will not make any difference to the SP. More news here that under normal circs should be moving the SP from £2 to perhaps nearer £26.
Unfortunately External factors NOT relevant to GSK are affecting SP, that is why it is lower.
This is the case with all investments all over this world.
Today’s S P drop is probably the biggest surprise on the market. Positive news on new reg approval seemed to have the opposite effect for GSK today!!
Not sure why the market has reacted in this way given there has been no negative news come to light.
.....re new possible drug approval for type of endometrial cancer deserves much better than another 1%+ off the SP.
Without the nagging Zantac issues, GSK would be priced at £25+, IMHO.